In this study the ability of malignant and normal progenitors in peripheral blood (PB) and bone marrow (BM) of CML patients in chronic phase to proliferate and produce mature progeny after transplantation into hereditary immunodeficient (SCID and NOD/SCID) mice was examined. Engraftment in NOD/SCID mice preconditioned by total body irradiation (TBI) alone was 10-fold higher than in SCID mice preconditioned by macrophage depletion and TBI, demonstrating that NOD/SCID mice are more 
Introduction
Chronic myeloid leukemia (CML) is a clonal cancer arising from neoplastic transformation of the hemopoietic stem cell (HSC). The hallmark of CML is the so-called Philadelphia (Ph) chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22. The translocation results in the formation of a chimeric oncogene based on the c-abl gene from chromosome 9 and the bcr gene on chromosome 22 . The bcr/abl oncogene encodes a protein with enhanced tyrosine kinase activity, which perturbs the proliferation and differentiation of the neoplastic stem cell and its progeny, eventually resulting in suppression of normal hemopoiesis and overgrowth by malignant cells. All myeloid lineages and often the B cell lineage as well are involved in CML, but expansion of the granulocyte lineage is usually most prominent.
Bone marrow (BM) and peripheral blood (PB) of newly diagnosed as well as treated chronic phase CML patients contain normal and malignant stem cells at variable frequencies. 1, 2 Thus, improved treatment strategies may be aimed at purification of normal stem cells for autografting or at selectively inhibiting the survival and outgrowth of Ph + cells, by exploiting differences in phenotype and/or growth properties between normal and malignant stem cells. [3] [4] [5] [6] [7] The development and successful implementation of more selective anti-neoplastic approaches in CML will require the availability of functional assays in which the effects of growth factors (GF), inhibitory cytokines and cytotoxic drugs on survival and outgrowth of normal and malignant stem cells can directly be compared in a quantitative manner. Long-term nonstromal cultures in defined serum-free medium have provided information about the GF requirements of immature normal and malignant progenitors. 8 Long-term culture and cobble-stone area forming cell (CAFC) assays supported by the murine stromal cell line FBMD-1 have been developed to examine the frequency of immature normal and malignant cells in purified subsets, as normal and malignant stem cells are maintained in this assay with similar efficiency 9 and these assays have been used to examine the differential responses to interferon-␣ of nonresponding vs responding CML patients at the stem cell level. 10 The regulatory mechanisms of proliferation and differentiation of human hemopoietic cells with in vivo hemopoietic capacity can also be studied in animal models using immunodeficient mouse strains. Severe combined immunodeficient (SCID) mice and non-obese diabetic SCID (NOD/SCID) mice have been shown to be suitable hosts for normal human hemopoietic cells from various sources, as well as for different types of human leukemias. [11] [12] [13] [14] [15] Cell lines and primary leukemic cells from acute (pre) B cell, T cell or myeloid leukemias proliferate extensively in SCID mice and show a highly reproducible pattern of infiltration reminiscent of that observed in patients. [16] [17] [18] [19] [20] [21] [22] [23] Ph + leukemic cell lines and primary blast crisis cells from CML patients also grow predominantly in immunodeficient mice, with exclusive production of Ph + cells. 24 Preferentially a reliable transplantation assay for chronic phase CML cells in immunodeficient mice will require that the mouse microenvironment can support the outgrowth of normal and malignant cells with in vivo reconstituting ability with similar efficiency. Only in case such conditions are met, a mouse transplantation assay for human CML cells will be valuable to study the different effects of cytokines, cytotoxic drugs or other agents on the survival and outgrowth of normal vs leukemic stem cells in vivo and to assess the feasibility of stem cell purification strategies to eliminate malignant cells from autologous grafts. In a recent study, BM and PB cells from chronic phase CML patients repopulated SCID mouse BM with levels of chimerism between 5 and 10% but only after injection of high cell numbers (8 to 14 × 10 7 low density cells). In other studies, higher engraftment levels were obtained in NOD/SCID mice. 25, 26 In the latter studies, purified CD34 + cells also engrafted if very large cell numbers were transplanted, similar to those used with unfractionated grafts, suggesting the CD34 + cells engrafted suboptimally. The majority of human colony-forming cells produced in SCID mice were Ph − , 24 while in another study, in which NOD/SCID mice were used, both normal and malignant progenitor cells were detected in the mice. 26 In this study, the degree of mosaicism of malignant and normal cells before transplantation and after engraftment in immunodeficient mice was evaluated. Specifically, we set out to compare the outgrowth of malignant and normal cells from individual CML patients in SCID and NOD/SCID mice and to assess the relative contribution of normal and leukemic progenitors to the various subsets of human hemopoietic cells produced in the NOD/SCID mouse.
Materials and methods

CML progenitor cells
Hemopoietic progenitor cells were obtained from 10 patients after informed consent. Two patients were diagnosed as CML blast crisis and progenitor cells were recovered directly from the peripheral blood (PB). Eight patients were diagnosed in first chronic phase CML. Progenitor cells were recovered directly either from BM or from PB in the recovery phase following high-dose chemotherapy using cytarabin and idarubicin. These progenitor cells were indicated as 'mobilized PB' (Table 1) . At the time of harvest, no blast cells were present in the chronic phase CML samples used in this study. Mononucleated cells were isolated by Ficoll density gradient centrifugation (1.077 g/cm 2 , Nycomed Pharma, Oslo, Norway), and were then cryopreserved in 10% dimethylsulphoxide, 20% heat-inactivated fetal calf serum (FCS) and 70% Hanks balanced salt solution (HBSS, Gibco, Breda, The Netherlands) at −196°C as described. 27 After thawing by stepwise dilution in HBSS containing 2% FCS, cells were washed with HBSS containing 1% FCS and used for flow cytometric analysis or subset purification and inoculation into NOD/SCID mice. The viability of the thawed cells was determined by staining with trypan blue.
Subset purification
Purification of CD34
+ cells was performed by positive selection using Variomacs Immunomagnetic Separation System as described 28 (CLB, Amsterdam, The Netherlands). The percentage of CD34
+ cells in the unseparated pool and in the selected CD34
+ and CD34 − cell fractions was determined by FACS analysis.
Transplantation of CML cells in immunodeficient mice
Female, specific pathogen-free (SPF) CB-17 scid/scid mice (SCID), 6 to 9 weeks of age, were obtained from Harlan, CPB, Austerlitz, The Netherlands. Non-obese diabetic SCID NOD/LtSz-scid/scid (NOD/SCID) mice were purchased from Jackson Laboratories, Bar Harbor, ME, USA. The mice were housed under SPF conditions in a laminar air flow unit and supplied with sterile food and acidified drinking water containing 100 mg/l ciprofloxacine (Bayer AG, Leverkusen, Germany) ad libitum, in accordance with institutional animal research regulations. The plasma Ig level of the mice was determined with an ELISA using a sheep anti-mouse antibody reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, Penzberg, Germany) and animals with plasma Ig levels over 40 g/ml were excluded. To deplete macrophages in SCID mice, 1 day prior to transplantation of hemopoietic cells, the SCID mice were injected i.v. into a lateral tail vein with 200 l liposome stock solution containing di-chloromethylene di-phosphonate (kindly provided by Dr JJ van Rooijen, Department of Biochemistry, Free University Amsterdam, The Netherlands; Cl 2 MDP was a gift of Boehringer Mannheim). 22, 29 In previous studies with human umbilical cord blood (UCB) and human acute leukemia cells, this approach required 10-fold fewer cells for similar levels of engraftment than conditioning with TBI alone. 22 Liposometreated SCID mice and untreated NOD/SCID mice received a dose of 3.5 Gy total body irradiation (TBI), delivered by a 137 Cs source adapted for the irradiation of mice (Gammacell, Atomic Energy of Canada, Ottawa, Canada), 2-4 h before transplantation. The transplants were suspended in 200 l HBSS containing 0.1% BSA (Sigma, Zwijndrecht, The Netherlands) and injected i.v. into a lateral tail vein.
In vitro colony assay
Mononuclear cells from patients' PB or BM and chimeric mouse BM samples were assayed for the presence of granulocyte-macrophage colony-forming units (GM-CFU) and erythroid burst-forming units (BFU-E) by in vitro colony formation in viscous methylcellulose culture medium as previously described. [30] [31] [32] Briefly, patients' cells or BM cells of mice 35 days post-transplantation were plated at concentrations of 0.5-4 × 10 5 /ml plated in 35-mm Petri dishes (Becton Dickinson). The cultures were maintained in a humidified atmosphere of 10% CO 2 at 37°C for 14 days, after which the colonies were counted. Data of duplicate dishes were expressed as average number of colonies per 10 5 cells plated. After counting, single colonies were plucked, centrifuged on glass slides and stored at −20°C until fluorescent in situ hybridization (FISH) was performed.
Tissue collections and analysis
After 35 days, mice were killed by CO 2 inhalation followed by cervical dislocation. From each mouse, both femurs were collected and BM cell suspensions were prepared by flushing with HBSS. After counting, the cells were cultured in colony assays and analyzed by flow cytometry to determine the percentage of human hemopoietic cells in the mouse bone marrow. Cells were suspended in HBSS containing 2% FCS, 0.05% (wt/vol) sodium azide, 2% human serum and 2% mouse serum and stained with the pan-leukocyte surface marker CD45 antibody conjugated with fluorescein isothiocyanate (FITC) and with CD33 antibody conjugated with R-phycoerythrin (PE), for 30 min, at 4°C. Positive samples were further analyzed by incubation with FITC and PE labelled mouse monoclonal antibodies to human CD34, CD19, CD16, CD15, CD38 (Becton Dickinson, San Jose, CA, USA), glycophorin A (GpA), CD3 and CD71 (Dako, Copenhagen, Denmark). Parallel samples were incubated with isotypematched control antibodies. Cell samples of non-transplanted mice were stained as negative controls. Fluorescence was measured using a FACScan flow cytometer and Lysis II or Cellquest software (Becton Dickinson). Dead cells were excluded from analysis by adding 1 g/ml propidium iodide (PI) and gating for PI − cells in the FL3 channel. For isolation of lineage subsets, isolated BM of chimeric mice transplanted with CML cells and thawed cells of three patients were stained with FITC and PE-conjugated antibodies against human CD15, CD33, CD19, CD34, CD71, CD45 (Becton Dickinson) and GpA for 30 min on ice in HBSS containing 2% FCS, 0.05% (wt/vol) sodium azide, 2% human serum and 2% mouse serum. After incubation, the cells were washed twice, resuspended in HBSS and sorted using a FACS Vantage or FACS Calibur flow cytometer (Becton Dickinson). Sorted subsets were centrifuged on slides (22 g, 5 min), fixed in methanol for 15 min and stored at −20°C until FISH was performed.
Fluorescent in situ hybridization (FISH)
FISH was performed as described previously. 9, 33, 34 In short, the BCR and ABL-specific DNA probe were labelled with biotin-16-dUTP and digoxigenin-11-dUTP (Boehringer), respectively, by nick translation. Cells were pre-treated in RNAse solution (200 g/ml in 2 × SSC buffer pH 7.0, 60 min at 37°C; 1 × SSC is 0.15 mol/l NaCl, 0.015 mol/l sodium citrate). Pepsin treatment was performed by incubating the slides for 10 min at 37°C in a HCl-pepsin solution (50 l saturated pepsin in 100 ml 0.01 N HCl). The slides were post-fixated in a 1% formaldehyde solution in PBS containing 50 mM MgCl 2 for 10 min at room temperature and dehydrated in an ethanol series. The BCR and ABL probes (5 g/ml) were denaturated for 4 min at 72°C. After denaturation and dehydration the cells were hybridized overnight at 37°C in a humidified atmosphere. The slides were incubated for 30 min at 37°C with avidin-FITC (2 g/ml, Vector Laboratories, Burlingame, CA, USA) in 4 × SSC containing 5% non-fat dry milk (NFDmilk) (protifar, Nutricia, Zoetermeer, The Netherlands). The fluorescence intensity was amplified using subsequent layers of sheep anti-Dig-rhodamine (Boehringer), diluted to 1 g/ml in Boehringer milk to block unspecific binding, anti-avidin (Brunschwig chemie; 2.5 g/ml in Boehringer milk), for 30 min at 37°C in a humidified atmosphere. After washing, the cells were incubated with donkey anti-sheep Texas Red (Jackson Immunoresearch Lab; 6.8 g/ml in Boehringer milk) and avidin-FITC (2 g/ml in Boehringer milk) for 30 min at 37°C in a humidified atmosphere. After washing, the cells were stained for total DNA with 4, 6-diamidino-2-phenylindole. 2HCl (DAPl; 0.1 g/ml Sigma) in 2.3% Vectashield (Vector Laboratory). The slides were analyzed using a fluorescent microscope equipped with a triple band pass filter for simultaneous excitation of FITC, Texas Red and DAPI. A random sample of at least 100 complete, non-overlapping nuclei was scored for green and red fluorescent spots and the frequency of Philadelphia chromosomes was determined. A cell was scored Ph − if two distinct red and two distinct green signals were visible within a nucleus. A cell was scored Ph + if it contained one distinct red signal, one distinct green signal and one distinct yellow signal representing the coincidence of a red and green signal or if it contained two distinct red signals and two green signals with one red and one green signal in close juxtaposition. As a positive control cytospin slides prepared from selected CD34
+ cells from a patient with established accelerated CML were used. Cytogenetic evaluation of these CD34
+ cells yielded 100% Ph + metaphases (30/30) without additional cytogenetic abnormalities and evaluation by FISH yielded positivity for bcr/abl of 97 ± 2% (n = 8). Normal PB or BM samples were used as negative controls in which 98 ± 1% (n = 8) cells were scored as Ph − . Individual FISH experiments were considered of sufficient quality if positive and negative controls yielded a percentage of more than 95% and less than 5%, respectivity. Flow cytometric analysis of chimeric mouse bone marrow stained with CD45-FITC vs CD33-PE (a). Positive staining for any of these markers was not found in non-transplanted mice (b), demonstrating the specificity of the antibodies for human cells.
Results
Chimeric bone marrow analysis
Low density CML cells were injected into parallel groups of SCID mice conditioned with TBI and macrophage depletion and in NOD/SCID mice conditioned with TBI alone. The level of chimerism in the mouse BM was assessed by flow cytometry 35 days after transplantation. The percentage CD45
+ cells was used as a measure for engraftment of human cells. Mice with Ͼ 1% CD45 + cells were considered to be engrafted. A representative result of chimeric BM stained with CD45-FITC vs CD33-PE is shown in Figure 1a . The presence of CD45 +
CD33
+ and CD45 + CD33 − cells demonstrated that human myeloid, as well as non-myeloid cells were present.
The ability of the SCID and NOD/SCID mice to support outgrowth of CML cells was compared in four separate experiments with samples of three patients (Figure 2 ). After transplantation with 10 7 to 3 × 10 7 unfractionated cells, SCID mice preconditioned by macrophage depletion and 3.5 Gy TBI displayed human cells in only eight of 24 mice transplanted at average levels of 5.9 ± 8.1%. NOD/SCID mice preconditioned with TBI alone showed higher levels of chimerism in 19 of 23 mice transplanted, ie 14.0 ± 13.5%. These results demonstrated that NOD/SCID mice provide better support for chronic phase CML cells with fewer graft failures than SCID mice. All further experiments were therefore performed with NOD/SCID mice.
As shown in Table 1 
Multilineage outgrowth of CML cells
The composition of the human cell population in the BM of mice with sufficiently high levels of chimerism, ie those transplanted with cells from patients 1-4 in Table 1 , was studied by flow cytometry using a panel of lineage-specific markers. The percentage of cells in each subset identified was expressed relative to the number of cells that stained with the pan-leukocyte marker CD45 (Figure 3 ). Mice transplanted with 15-20 × 10 6 CML cells from patients 1 (Figure 3a) , 2 ( Figure 3b) and 3 (Figure 3c ) showed multilineage outgrowth, although the relative frequencies of the various cell types were variable. The most prominent population in mice transplanted with cells from patients 1 to 3 was the myeloid subset (79 ± 24% of the human CD45
+ cells, n = engrafted with low frequencies of human cells (4%) after transplantation with 20 × 10 6 low density cells from patient 4 (Figure 3d ). In these mice only CD38
+ cells which were CD4 + and/or CD8 + were detected, indicating that these mice were engrafted with activated mature T-lymphocytes. FISH analysis of these cells with BCR and ABL specific probes revealed that virtually all of these T cells were Ph − , probably derived from expanding mature non-malignant T cells (data not shown).
FISH analysis on sorted hemopoietic subsets
Human CD45
+ cells were purified from chimeric mouse BM by FACS sorting in order to examine the contribution of normal and leukemic cells to engraftment of human cells in NOD/SCID mice. In addition, myeloid, erythroid, B-lymphoid and immature cells were purified from mouse BM, using the markers and sort regions shown in Figure 4 . The relative contribution of Ph + and Ph − cells to engraftment of these subsets was evaluated by FISH analysis using BCR and ABL specific probes. To examine to what extent outgrowth of normal and malignant cells in the mice reflects the mosaicism of Ph + and Ph − cells in the patient, the frequencies of Ph + cells in the subsets sorted from the chimeric mouse BM were compared to the frequencies in corresponding subsets sorted directly from cryopreserved patient BM cells (Table 2) . Ph + as well as Ph − cells were present in sorted cell popu- 
Table 2
Ph-chromosome frequency in sorted subsets lations for all three patients tested. Sorted CD45 + cells obtained directly from cryopreserved PB samples of these patients contained similar numbers of Ph + cells as compared to the CD45 + cells recovered from the mice. The frequencies of Ph + and Ph − cells in the immature CD34 + subset and in the monocyte, granulocyte, and erythroid populations did not differ from the cells isolated directly from the patient samples and from the engrafted NOD/SCID mice. Ph + as well as Ph − B-lymphocytes were detectable in primary cells from patient 1 and 2 and in BM of chimeric mice transplanted with cells from these patients. The Ph + frequency of B cells isolated from the mouse BM were higher as compared to the Ph + frequency in patients 1 and 2 (two-fold and three-fold, respectively), compared to the Ph + frequency in patients 1 and 2 (two-fold and three-fold, respectively), suggesting selective outgrowth of Ph + B cells in the NOD/SCID mice. All B cells detected in primary cell samples from patient 3 and in chimeric BM of mice transplanted with cells of this patient were Ph − ( Table  2) . These results demonstrated that both normal and malignant cells obtained from individual CML patients engraft the BM of sublethally irradiated NOD/SCID mice and contribute to multilineage outgrowth of human cells. Moreover, the Ph distribution pattern of immature cells and cells of the myeloid and erythroid lineages present in the graft is recovered unchanged after transplantation, without selective outgrowth of either normal or malignant cells. The frequency of Ph + cells in the PB of all three patients examined and in the BM of the engrafted mice was much lower than can be expected for chronic phase CML patients. However, morphological analysis of cells of these patients revealed relatively large frequencies (34%, 9% and 33%, respectively) of immature myeloid precursors and relatively few mature granulocytes (2%, 3% and 5%, respectively). The relative low number of mature Ph + granulocytes and predominance of Ph − CD34 + cells in the patients' PB samples as well as in chimeric mouse BM were consistent with the relatively strong contribution of Ph − precursor cells to the circulating cell population after mobilizing chemotherapy in chronic phase CML patients.
35-37
Maintenance of primitive cells in NOD/SCID mice
In addition to mature cells, BM of mice repopulated with cells from patients 1, 2 and 3 also contained immature CD34 + cells, in frequency ranging from 0.2 to 27% (Figure 3) . Comparison of the absolute number of CD34 + cells in these mice to the number of CD34 + cells in the grafts showed that CD34 + cell numbers were maintained or increased up to six-fold during the 35-day engraftment period (Table 1) . CD34
+ CD38 − cells were not found in the chimeric BM, suggesting there was no maintenance of this primitive cell population in the engrafted NOD/SCID mice (data not shown). Clonogenic myelomonocytic and erythroid progenitors, ie CFU-GM and BFU-E, were identified in engrafted mouse BM but generally in numbers lower than the CFU-GM numbers injected (Table 3) . CFU-GM numbers had increased 1.5 to 5.6-fold relative to input numbers in only five of 14 mice transplanted with low density or purified CD34
+ cells. BFU-E were also detected in engrafted 624 mice, but in most mice BFU-E numbers were lower than in the graft (Table 3) . The low and variable recovery of clonogenic human progenitors could be attributed to the absence of detectable Ph + progenitors among the human progenitors cultured from chimeric mouse BM (Table 4) . In contrast to the results obtained with the human cell subsets sorted directly from the chimeric BM, BFU-E and CFU-GM colonies grown from chimeric mouse BM were Ph − , whereas a significant number of colonies grown directly from the patient samples did contain the Ph chromosome. These results suggested that malignant progenitors with in vitro clonogenic ability were maintained less efficiently in mice than their normal counterparts.
Engraftment of NOD/SCID mice with cells from CML patients in blast crisis
PB cells of two CML patients (Nos 9 and 10) in blast crisis were transplanted into NOD/SCID mice in order to compare the engraftment characteristics of these cells to those of chronic phase CML. Transplantation with 5 × 10 7 low density cells resulted in high levels of chimerism (patient 9: 72 ± 6%, n = 5; patient 10: 51 ± 9, n = 6) in all mice injected ( Table  1) . Immunophenotyping of the human cells produced in mice transplanted with cells from patient 9, showed that most cells co-expressed CD34 and CD19 which was similar to the phenotype of the blast cells in the graft and indicated that the engrafting cells were mainly derived from a leukemic B cell precursor. CD33 was also expressed on ෂ40% of the cells Table 4 Clonogenic human progenitors from engrafted mouse BM are Ph ( Figure 5a ), demonstrating that the mice were engrafted with cells with mixed phenotype, a feature frequently observed with lymphoid blast crisis. 38 Cells produced in the mice as well as in the graft of patient 10, mostly expressed myeloid markers (CD15, CD33) (Figure 5b ), indicating that the engrafting cells were mainly derived from a leukemic myeloid precursor. A large proportion of engrafted cells were Ph + , ie 82 ± 3% for patient 9 and 87 ± 4% for patient 10. A similar frequency of Ph + cells was also detected in the grafts. The frequency of 10-20% Ph − cells was significantly higher than the frequency of 'false negative' Ph − cells, ie 2 ± 1%, measured by FISH analysis of uniformly Ph + cells. These results suggest that residual non-malignant cells with in vitro repopulating potential can be detected in NOD/SCID mice transplanted with cells from blast crisis CML patients.
Discussion
The present study shows that both normal and malignant progenitor cells from CML patients can be transplanted successfully into NOD/SCID mice with production of granulocytes, monocytes, erythroid cells, B-lymphocytes and immature, CD34 + progenitors. In addition, levels of Ph + /Ph − mosaicism of sorted subsets recovered after engraftment reflected the degree of mosaicism before transplantation. Engraftment of cells from chronic phase CML patients in NOD/SCID mice conditioned with 3.5 Gy TBI was more prominent than in SCID mice preconditioned with TBI supplemented with the injection of Cl 2 MDP liposomes. This is in contrast to studies with human UCB, in which engraftment levels of unfractionated, as well as purified CD34
+ and CD34 + CD38 − cells in macrophage-depleted SCID mice and NOD/SCID mice preconditioned with TBI alone were similar 15 and suggests that the additional NK cell and macrophage defects of NOD/SCID mice are necessary to achieve engraftment of normal and malignant cells from CML PB.
A useful animal model for chronic phase CML should support and maintain the outgrowth of normal and malignant progenitors, because chronic phase CML is clinically characterized by a mosaicism of Ph + and Ph − progenitors. In addition, only NOD/SCID mice with a stable mosaicism which reflects the relative frequencies of Ph + and Ph − cells in the patients' blood and BM may allow the evaluation of treatment strategies aimed at a selective outgrowth of normal as opposed to malignant cells. It was, therefore, important to evaluate the capacity of normal and leukemic cells from individual patients for engraftment and subsequent outgrowth in NOD/SCID mice. FISH analysis of sorted subsets demonstrated that the distribution of the Ph chromosome in all human cell subsets remained in the same order of magnitude in all human subsets isolated from chimeric mouse BM as compared to the same subsets isolated directly from BM or PB from these patients. These results demonstrated that both normal and malignant progenitor cells proliferate and differentiate in BM of transplanted NOD/SCID mice, resulting in production of human cell populations in mice, which display a similar Ph distribution as the cells in the original graft. The percentages of Ph + leukocytes as presented in Table 2 appeared low as compared to what can be expected for patients in first chronic phase CML. However, the patients used in our study were treated with intensive chemotherapy including idarubicin and cytarabin and the cell samples used for NOD/SCID mouse transplantation were obtained in the recovery phase. It is known that Ph − precursor cells can effectively be mobilized into the peripheral blood following intensive chemotherapy and that peripheral blood stem cell harvests may even be largely devoid of malignant precursors, as demonstrated by cytogenetic analysis. 36, 37 In previous studies we have analyzed the maintenance of Ph + and Ph − progenitors of purified subsets of CD34 + cells in LTC and CAFC assays, supported by the FBMD-1 stromal cell line. 9, 10 The results of a large group of patients, including one which was tested in NOD/SCID mice in the present study (patient 3), showed that Ph + and Ph − cells are produced with similar efficiency in long-term cultures. + cells in the NOD/SCID mice clearly demonstrates that multilineage progenitors and not exclusively myeloid progenitors were responsible for in vivo engraftment. However, analysis of the clonal origin of the engrafted cells, eg using retroviral-mediated gene marking, will be needed to definitively establish the relative contribution of multipotent as compared to committed progenitors to in vivo engrafment.
In recent studies, analysis of Ph + and Ph − colonies, grown from human cells under conditions that permit outgrowth of human but not of murine progenitors, recovered from NOD/SCID mice demonstrated production of normal, as well as leukemic colony-forming cells in engrafted mice as examined by analysis of metaphase chromosomes, 25, 26 whereas in an earlier study in SCID mice normal progenitors made up the majority (70%) of the human hemopoietic cells present. 24 Since in those studies no comparison was made with the relative frequencies of Ph + and Ph − progenitors in the graft, it is difficult to assess whether the different results reflected a more efficient maintenance of Ph + progenitors in NOD/SCID as compared to SCID mice, or were caused by variations between individual patients with respect to the relative number of Ph + and Ph − progenitors. 24, 26 In our study, all human monomyeloid and erythroid colonies grown from chimeric mouse BM were Ph − . This was in contrast to the mosaicism of Ph + and Ph − cells observed for the noncultured human cell subsets isolated directly from patients' PB and chimeric mouse BM, and for the monomyeloid and erythroid progenitors grown directly from the graft. Explanations for the discrepancy between the Ph + cell frequencies of clonogenic progenitors 626 and sorted human cell subsets may include qualitative differences between the ability of Ph + and Ph − NOD/SCID engrafting cells to maintain or produce clonogenic progenitor cells in vivo. In particular, the mouse micro-environment may provide less effective support for maintenance or production of immature Ph + progenitors with in vitro clonogenic ability than for normal immature cells. Alternatively, the malignant progenitors may have a shorter transit time than their normal counterparts in a mouse micro-environment, accounting for a lower Ph + progenitor frequency while maintaining relatively large numbers of more mature offspring. In any case, the absolute number of colony-forming cells recovered from the chimeric mouse BM was low, with large variations between individual mice ( Table 3) . As shown in this study phenotypically identified subsets of human cells can be isolated from the BM of engrafted mice in sufficiently large cell numbers for reproducible FISH analysis, and thus provide more quantitative information about engraftment of normal and leukemic cells than can be obtained by analysis of individual colonies.
In our study, no evidence was found for the maintenance of immature CD34 +
CD38
− CML or normal cells in engrafted NOD/SCID mice or for significant amplification of either normal or leukemic CD34
+ cells and clonogenic progenitors in vivo. This contrasts with our previous study using UCB cells, which also did not require exogenous human growth factor support, but which showed significant expansion of CD34 + cells and clonogenic progenitors. 15 In that study, we noted independent control of immature CD34 + CD38 − cell expansion and mature cell outgrowth, the former requiring support by CD34
+ accessory cells present in the graft. Therefore, from the present study we speculate that CML cells and their progeny may similarly require accessory cell and/or growth factor support to display their full potential for immature cell amplification and outgrowth in the NOD/SCID environment. In recent studies, injection of stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and PIXY321 (fusion protein of IL-3 and GM-CSF) failed to improve the overall engraftment levels, suggesting that the stimuli provided by the mouse micro-environment are sufficient for outgrowth of human cells. 24, 25 Treatment with SCF, but not GM-CSF or G-CSF selectively promoted the engraftment and proliferation of leukemic cells in vivo, 25 suggesting that exogenous GF support can change the balance between Ph + and Ph − progenitors that are produced in vivo. It remains to be established as to whether exogenous GF support can also promote the maintenance and expansion of immature CD34 +
− cells in vivo. If such conditions can be developed it will be possible to use the NOD/SCID mouse transplantation assay not only to study outgrowth of normal and malignant cells, but also to test stimuli that can differentially promote the maintenance or expansion of normal cells and elimination of leukemic stem cells in vivo.
Cells from BC patients engrafted to much higher levels with less variation of engraftment levels in individual mice than cells from chronic phase CML patients. The engraftment potential of CML BC cells thus resembles that of leukemic blasts from AML patients, which also engraft efficiently in immunodeficient mice, [19] [20] [21] whereas the much lower and less reproducible engraftment of chronic phase CML cells is more similar to that obtained with normal human BM or mobilised PB cells. 40, 44 The variable engraftment obtained with different human cell types may reflect difference in requirements for cytokines or stromal factors, or in the ability of engrafting cells from different sources to home to the mouse BM.
In conclusion, the present study provides evidence for multilineage outgrowth of chronic phase and blast crisis CML in transplanted NOD/SCID mice. Levels of Ph + /Ph − mosaicism did not differ before and after transplantation. Thereby the model will in principle be useful to examine the feasibility of cell fractionation approaches and other ex vivo manipulations to eliminate transplantable malignant stem cells from autografts and to evaluate the differential effects of growth factors, inhibitory cytokines or cytotoxic drugs on the survival and differentiation of normal vs leukemic stem cells. In addition, mice engrafted with chronic phase CML cells may be exploited to study the development of CML from chronic phase towards acceleration and blast crisis and to test treatment strategies to prevent this process.
